Maximising the impact of Biosimilar Medicines requires strategic action in Europe

Medicines for Europe Statement on Unitary SPC Legislative Process

Joint Industry Statement on EU-Mercosur Negotiations

Council adoption of Urban Waste Water Treatment Directive will generate a tsunami of essential and critical medicine shortages across Europe

New report highlights market access barriers for EU-based generic and biosimilar companies in third countries

Urban Wastewater Treatment Directive risks undoing Europe’s efforts to improve the availability, affordability and accessibility of medicines

Medicines for Europe delegation leads on manufacturing, sustainability and access at CPHI congress

EU Critical Medicines Act must protect secure supply of essential medicines

Availability of Treatment in Slovakia within the framework of European Legislation – Expert Forum Brings Solutions

The international conference Expert Forum, organized by the GENAS association, attracted key healthcare players to Bratislava on Monday, including representatives from the European Commission (DG SANTE), the Permanent Representation of the Slovak Republic to the EU, Medicines for Europe, Slovak and European experts and analysts. The participation of significant stakeholders underscores the importance of the topic of treatment availability and the need for discussion on current challenges and solutions, all in the context of the ongoing revision of EU pharmaceutical legislation.

Open

Prioritising access and EU solidarity should drive Health Ministers’ agenda in next EU talks

Ministers of Health will meet in Brussels on Friday 21^st June to discuss EU coordination on health. Ahead of this meeting, Medicines for Europe calls on Member States, including small Member States and Central Eastern Europe Countries, to prioritise equitable access for all patients.

Open